Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ALS drug QRL-201 enters human safety testing

NCT ID NCT05633459

Ongoing Disease control Sponsor: QurAlis Corporation Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether a new drug called QRL-201 is safe and tolerable for people with ALS (Lou Gehrig's disease). About 69 adults aged 18-80 with recent ALS symptoms will receive either the drug or a placebo. The main goal is to check for side effects, not to cure the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

  • CHUM - Hopital Notre-Dame

    Montreal, Quebec, H2L 4M1, Canada

  • Charité Research Organisation

    Berlin, 10117, Germany

  • Deutsches Zentrum für Neurodegenerative Erkrankungen e. V. (DZNE)

    Bonn, North Rhine-Westphalia, 53127, Germany

  • Kings College Hospital NHS Foundation Trust

    London, SE5 9RS, United Kingdom

  • Montreal Neurological Institute-Hospital

    Montreal, Quebec, H3A 2B4, Canada

  • National Hospital for Neurology and Neurosurgery

    London, WC1N 3BG, United Kingdom

  • St James's Hospital

    Dublin, D08 A978, Ireland

  • Sunnybrook Health Science Centre

    Toronto, Ontario, M4N 3M5, Canada

  • The University of Sheffield, Royal Hallamshire Hospital

    Sheffield, United Kingdom, S10 2JF, United Kingdom

  • Universitair Medisch Centrum Utrecht

    Utrecht, Netherlands

  • Universitaire Ziekenhuizen Leuven (UZ Leuven)

    Leuven, B-3000, Belgium

  • University Hospital Schleswig-Holstein (UKSH) Campus Lübeck, Department for Neurology/ Precision Neurology

    Lübeck, Germany

  • University of Alberta

    Edmonton, Alberta, T6G 2G3, Canada

  • University of Calgary

    Calgary, Alberta, T2N 1N4, Canada

  • Universitätsklinikum Ulm

    Ulm, 89081, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.